NCT05146973已完成2 期
A Single Arm, Phase 2 Trial of External Beam Radiation Therapy (EBRT) in Combination With 177Lu-DOTA-TLX591-CHO in Patients With Biochemically Recurrent Oligometastatic, Prostate Specific Membrane Antigen-Expressing Prostate Cancer
Telix Pharmaceuticals (Innovations) Pty Limited4 个研究点 分布在 1 个国家目标入组 5 人开始时间: 2022年8月30日最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 5
- 试验地点
- 4
- 主要终点
- To determine Prostate Specific Antigen Progression Free Survival (PSA PFS)
研究概览
简要总结
This is a phase II trial to evaluate the therapeutic efficacy of a radiolabelled PSMA-targeting antibody, 177Lu-TLX591, given in combination with external beam radiation therapy (EBRT) in patients with biochemically recurrent, oligometastatic, PSMA-expressing prostate cancer. TLX591 is being developed as a PSMA-targeting antibody to be radiolabelled with a therapeutic radioisotope for the treatment of PSMA-expressing tumours.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- Male
- 接受健康志愿者
- 否
入选标准
- •Signed Informed Consent Form
- •Male, aged ≥ 18 years
- •Estimated life expectancy of at least 6 months
- •Eastern Cooperative Oncology Group (ECOG) score 0 - 2
- •Biopsy proven prostate adenocarcinoma with Gleason Score 7 or more at primary presentation
- •Previous Radical Prostatectomy (RP) with curative intent (+/- post-operative radiotherapy to prostate bed)
- •Biochemical relapse, as defined by EAU-ESTRO-SIOG Guidelines (serum PSA > 0.2 ng/mL, confirmed by repeat measurements)
- •PSMA-ligand avid pelvic nodal disease on PSMA-ligand PET/CT, with visualised disease confined to the pelvis with or without evidence of PSMA-avid disease in the prostate bed
- •At least one pelvic nodal lesion ≥ 5 mm in the greatest dimension. SUVmax > 9 in enlarged nodes; SUVmax > 3 in nodes 5 mm or less
- •Oligometastatic disease as defined by ≤ 5 metastatic lymph nodes
- •Metastatic lymph nodes not beyond the aortic bifurcation
- •Non-castrate levels of testosterone (> 20 ng/dL)
- •Chemotherapy naïve
- •Adequate renal function: Cr Cl ≥ 40 mL/min (determined by Cockcroft-Gault formula)
- •Adequate bone marrow function: Hb > 90 g/L; platelets > 100 x 109/L; neutrophils > 1.5 x 109/L
- •Adequate liver function: bilirubin < 1.5 x upper limit of normal (ULN); AST, ALT, ALP < 2 x ULN; albumin > 30 g/L
- •Willing and able to comply with all trial requirements, including all treatments and pre- and post-treatment assessments
- •Able to commence treatment within 28 days of enrolment
排除标准
- •Previous external beam radiotherapy to pelvis for other malignancies or medical conditions (except for post-operative prostate bed radiotherapy for prostate cancer)
- •Androgen deprivation therapy within 12 months of trial screening
- •Known androgen deficiency
- •Bone or visceral metastases
- •Lymph node metastases above the aortic bifurcation
- •Contraindications to pelvic irradiation as determined by Investigator (e.g., chronic inflammatory bowel disease)
- •At increased risk of haemorrhage, or recent history of a thrombotic event (e.g., Deep Vein Thrombosis [DVT]/Pulmonary Embolism [PE]) and/or are using long-term anti-coagulant or anti-platelet agents)
- •Known hypersensitivity to any isotope of lutetium (Lu) in any chemical form, or any isotope used in PSMA imaging
- •Contraindication to intravenous contrast
- •Evidence of urinary tract stricture, or significant urinary/faecal incontinence Presence of active infection at time of screening, or history of serious infection within the previous 4 weeks
- •History of any malignancy other than prostate cancer within 5 years of enrolment (excluding localised non-melanoma skin cancers)
- •Any uncontrolled significant medical, psychiatric, or surgical condition (e.g., active infection, unstable angina pectoris, cardiac arrhythmia, poorly controlled type 2 diabetes, uncontrolled congestive heart failure, pulmonary disease), or laboratory findings that, in the opinion of the Investigator, may jeopardise the participant's safety or that would limit compliance with the treatment and assessment requirements of the trial
- •Any cognitive impairment or other condition that may render the participant unable to adequately understand the requirements, nature, and possible consequences of the trial.
- •Intention to father children within a timeframe corresponding with the duration of the allocated treatment regime plus 12 weeks.
研究组 & 干预措施
Single administration of 177Lu-DOTA-TLX591
Experimental
Two single IV infusions of 76 mCi (2.8 GBq) each (equivalent to a 45 mCi/m2 administered activity in a standard 1.7m2 individual) of 177Lu-DOTA-TLX591, given 14 days apart.
干预措施: 177Lu-DOTA-TLX591 (Biological)
结局指标
主要结局
To determine Prostate Specific Antigen Progression Free Survival (PSA PFS)
时间窗: Through study completion, up to 2 years
The time from enrolment to time of PSA increase greater than 25%
次要结局
未报告次要终点
研究者
研究点 (4)
Loading locations...
相似试验
招募中
2 期
Study Evaluating Dosimetry, Randomized Dose Optimization, Dose Escalation and Efficacy of Ac-225 Rosopatamab Tetraxetan in Participants With PSMA PET-Positive Castration-Resistant Prostate Cancer (CRPC)PSMA PET-Positive Castration-Resistant Prostate CancerNCT06549465Convergent Therapeutics93
已完成
2 期
Efficacy of Radium 223 in Radioactive Iodine Refractory Bone Metastases From Differentiated Thyroid CancerThyroid CancerNCT02390934Gustave Roussy, Cancer Campus, Grand Paris13
招募中
2 期
Study of Palliative Radiation Combined with Pembrolizumab in Unresectable Metastatic Stage IV Breast CancerMetastatic Breast CancerNCT04990921University of Louisville15
进行中（未招募）
2 期
Sunvozertinib (DZD9008) in Pretreated Lung Cancer Patients with EGFR Exon20 Insertion Mutation (WU-KONG6)Non-Small Cell Lung CancerNCT05712902Dizal Pharmaceuticals104
已完成
2 期
Safety and Immune Response of One Dose of OVX836 at Two Dose Levels, in Comparison to Influvac TetraTM, After Intramuscular Administration in Healthy Subjects Aged 18-65 YearsInfluenzaNCT04192500Osivax300